AB0431 THE EFFICACY OF BELIMUMAB (BEL) AS A SPARING CORTICOSTEROID AGENCY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Background Patients with SLE are recommended to continue the maintenance therapy as less glucocorticoid possible.1) However, tapering often results in recurrence of SLE. Current reports suggested that adding BEL standard could lead reduction and SLE.2) Objectives The aim this study is evaluate efficacy safety co-treatment Methods Fourteen patients receiving were enrolled study. Dose prednisolone (PSL), titer anti-DNA antibody, WBC count, serum complement disease activity index (SLEDAI) examined retrospectively at baseline 24 months after administration BEL. Results At baseline, mean age was 48 years old, 11 female, duration 8.6 years. dose PSL significantly reduced (meansease apre-administration BEL:6.1±1.1 mg/day, BEL: 1.2 p=0.001 ). Furthermore, six (43 %) withdraw without flare disease. There also statistical significance about SLEDAI between treatment by BEL(2.1patients c p=0.03 ) antibody (6.8 t no significant count (6177out fla7e d p=0.24 (C3 87significant (61 p=0.78 , C4 20erum 87signif p=0.54 As for adverse event, bacterial pneumonia (n=1) pulmonary cryptococcosis revealed. Conclusion Our on enable prevent reduce among under In almost half cases, flare. References [1] Ann Rheum Dis 2019; 78: 736-745. [2] 2018; 77: 355-745. Disclosure Interests None declared